The NeurologyLive® epilepsy clinical focus page provides information, podcasts, videos, and news about the latest FDA actions, clinical guideline updates, study and clinical trial findings, and interviews with physicians related to epilepsy and related epileptic conditions, including Lennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex, focal seizures, nonmotor seizures, and more.
August 13th 2025
New study reveals vormatrigine significantly reduces focal onset seizures, offering hope for improved epilepsy treatments at the upcoming International Epilepsy Congress.
Updates in Therapeutic Development: Clinical Trial Readouts to Watch in the First Half of 2025
January 29th 2025Explore some of the most highly anticipated clinical trials with data readouts expected in the second half of 2025—key updates that researchers and clinicians in neurology won’t want to miss.
Insights From the Pediatric Epilepsy Research Consortium on Advancing Genetic Testing
January 29th 2025A duo of experts discussed the importance of addressing barriers such as provider comfort, access to genetic counselors, and insurance coverage to reduce diagnostic latency and standardize genetic testing for epilepsy. [WATCH TIME: 5 minutes]
Pediatric AES Insights: Addressing Health Disparities and Advancing Neonatal Epilepsy Care
January 26th 2025Pediatric epilepsy specialists Adam Numis, MD, and Laura Kirkpatrick, MD, highlighted efforts to standardize data collection for pediatric epilepsy health equity and improve neonatal epilepsy outcomes.
Insights From AES 2024: Advancements and Challenges in Epilepsy Care
January 23rd 2025Leah Blank, MD, an assistant professor of neurology, population health, science, and policy at the Icahn School of Medicine provided commentary on some of the experience and positive movement from the 2024 American Epilepsy Society Annual Meeting.
Optimizing Epilepsy Treatments: Stiripentol’s Role in Dravet Syndrome
January 13th 2025James Wheless, MD, FAAP, FAAN, FAES, Le Bonheur Chair in Pediatric Neurology at the University of Tennessee Health Science Center, shared insights on his presentation from AES 2024, focusing on stiripentol, an FDA-approved treatment for Dravet syndrome.
Epilepsy Agent RAP-219 Shows Promising Safety, Target Occupancy Across Phase 1 Studies
January 12th 2025An ongoing phase 2a study of RAP-219 involves adult patients with drug-resistant epilepsy who have an implanted responsive neurostimulation (RNS) device, allowing for real-time monitoring of intracranial EEG data.
Stoke Announces Phase 3 EMPEROR Registrational Study for Zorevunersen in Dravet Syndrome
January 8th 2025The global Phase 3 trial aims to enroll ~150 patients with Dravet syndrome who have SCN1A variants, assessing zorevunersen's impact on seizure frequency, behavior, cognition, and safety over 60 weeks, with results expected by 2027.
Reducing the Burden: Proactive Care Strategies for Lennox-Gastaut Syndrome
January 7th 2025Babitha Haridas, MD, MBBS, a pediatric epileptologist at Johns Hopkins Medicine, discussed the complexities with managing status epilepticus in Lennox-Gastaut syndrome, focusing on the importance of identifying triggers early in their condition.